ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Biogen and Merck KGaA, Darmstadt, Germany side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BiogenMerck KGaA, Darmstadt, Germany
studies on the registry549523
open to participants now2817
phase 3 studies under way197
reach primary completion within a year157
programswith a study of their own in two years1114

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBiogenMerck KGaA, Darmstadt, Germany
Phase 1

Biogen: 3 of its 11 programs at phase 1

  1. BIIB142phase 1
  2. BIIB144phase 1
  3. BIIB145phase 1
27%

Merck KGaA, Darmstadt, Germany: 6 of its 14 programs at phase 1

  1. PARP1 Inhibitor HRS-1167phase 1
  2. M5542phase 1
  3. Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324phase 1
  4. M7437phase 1
  5. Contraceptives, Oral, Combinedphase 1

and 1 more — sign in to see them all

43%
Phase 2

Biogen: 1 of its 11 programs at phase 2

  1. BIIB147phase 2
9%

Merck KGaA, Darmstadt, Germany: 2 of its 14 programs at phase 2

  1. mirdametinibphase 2
  2. pimicotinibphase 2
14%
Phase 3

Biogen: 5 of its 11 programs at phase 3

  1. felzartamabphase 3
  2. pegcetacoplanphase 3
  3. salanersenphase 3
  4. omaveloxolonephase 3
  5. diroximel fumaratephase 3
45%

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at phase 3

  1. enpatoranphase 3
  2. precemtabart tocentecanphase 3
  3. evobrutinibphase 3
21%
Approved, new studies

Biogen: 2 of its 11 programs at approved, new studies

  1. tofersenapproved, new study
  2. Dimethyl Fumarateapproved, new study
18%

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at approved, new studies

  1. nirogacestatapproved, new study
  2. follitropin alfaapproved, new study
  3. lutropin alfaapproved, new study
21%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Biogen4 readouts · 2 phase 3·

Biogen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. felzartamabphase 3 · Dec 1 · NCT06685757
·

Biogen, Feb ’27: 1 program whose next study reaches primary completion

  1. BIIB145phase 1 · Feb 2 · NCT07225517
··

Biogen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tofersenapproved, new study · May 26 · NCT07223723

Biogen, Jun ’27: 1 program whose next study reaches primary completion

  1. pegcetacoplanphase 3 · Jun 25 · NCT07215390
····
Merck KGaA, Darmstadt, Germany5 readouts · 2 phase 3

Merck KGaA, Darmstadt, Germany, Nov ’26: 1 program whose next study reaches primary completion

  1. mirdametinibphase 2 · Nov 27 · NCT06997276
··

Merck KGaA, Darmstadt, Germany, Feb ’27: 1 program whose next study reaches primary completion

  1. PARP1 Inhibitor HRS-1167phase 1 · Feb 22 · NCT06421935
··

Merck KGaA, Darmstadt, Germany, May ’27: 1 program whose next study reaches primary completion

  1. nirogacestatapproved, new study · May 28 · NCT07170644
···

Merck KGaA, Darmstadt, Germany, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. follitropin alfaapproved, new study · Sep 30 · NCT07340827
  2. lutropin alfaapproved, new study · Sep 30 · NCT07340827
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Biogen

New programs 1

  • BIIB147phase 2 · first study · Sep 28 · Amyotrophic Lateral Sclerosis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Merck KGaA, Darmstadt, Germany

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionBiogenMerck KGaA, Darmstadt, Germany
Multiple Sclerosisboth · compare here

Biogen in Multiple Sclerosis: 2 programs

  1. diroximel fumaratephase 3
  2. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Multiple Sclerosis in search

Merck KGaA, Darmstadt, Germany in Multiple Sclerosis: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Multiple Sclerosis in search

Multiple Sclerosis, Relapsing-Remittingboth · compare here

Biogen in Multiple Sclerosis, Relapsing-Remitting: 2 programs

  1. diroximel fumaratephase 3
  2. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Multiple Sclerosis, Relapsing-Remitting in search

Merck KGaA, Darmstadt, Germany in Multiple Sclerosis, Relapsing-Remitting: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Multiple Sclerosis, Relapsing-Remitting in search

Arthritis, Rheumatoidboth · compare here

Biogen in Arthritis, Rheumatoid: 1 program

  1. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Arthritis, Rheumatoid in search

Merck KGaA, Darmstadt, Germany in Arthritis, Rheumatoid: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Arthritis, Rheumatoid in search

Breast Neoplasmsboth · compare here

Biogen in Breast Neoplasms: 1 program

  1. omaveloxolonephase 3

Their studies: Biogen’s studies of Breast Neoplasms in search

Merck KGaA, Darmstadt, Germany in Breast Neoplasms: 1 program

  1. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Breast Neoplasms in search

Melanomaboth · compare here

Biogen in Melanoma: 1 program

  1. omaveloxolonephase 3

Their studies: Biogen’s studies of Melanoma in search

Merck KGaA, Darmstadt, Germany in Melanoma: 1 program

  1. mirdametinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Melanoma in search

Multiple Myelomaboth · compare here

Biogen in Multiple Myeloma: 1 program

  1. felzartamabphase 3

Their studies: Biogen’s studies of Multiple Myeloma in search

Merck KGaA, Darmstadt, Germany in Multiple Myeloma: 1 program

  1. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Multiple Myeloma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Biogen 5 of 11 · Merck KGaA, Darmstadt, Germany 9 of 14 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.